Infection Number of participants diagnosed with infection · heart transplant recipients
Interleukin‐2 RA induction showed no clear difference in infection Number of participants diagnosed with infection compared with monoclonal antibody induction (low certainty).
1 finding from 1 review
CMV infection · heart transplant recipients
Interleukin‐2 RA induction showed no clear difference in cytomegalovirus infection Number of participants diagnosed with CMV… compared with monoclonal antibody induction (low certainty).
1 finding from 1 review
Post‐transplantation lymphoproliferative disorder Number of participants diagnosed with PTLD · heart transplant recipients
Interleukin‐2 RA induction showed no clear difference in post‐transplantation lymphoproliferative disorder Number of… compared with monoclonal antibody induction (low certainty).
1 finding from 1 review
Cancer · heart transplant recipients
Interleukin‐2 RA induction showed no clear difference in cancer Number of participants diagnosed with cancer compared with monoclonal antibody induction (low certainty).
1 finding from 1 review
Failure of acute rejection reversal · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) showed no clear difference in failure of acute rejection reversal compared with other antibody (stratified by comparator) (moderate certainty).
1 finding from 1 review
Recurrent rejection · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) showed no clear difference in recurrent rejection compared with other antibody (stratified by comparator) (moderate certainty).
1 finding from 1 review
Treatment adverse events: fever, chills, malaise after drug administration · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) may leads to higher treatment adverse events: fever, chills, malaise after drug… compared with other antibody (stratified by comparator) (low certainty).
1 finding from 1 review
Neurological adverse effects · kidney transplant recipients: first rejection episode
Muromonab‐CD3 (T cell) may leads to higher treatment adverse events: neurological side effects compared with other antibody (stratified by comparator) (low certainty).
1 finding from 1 review
Antiviral response ‐ 0.5mg/Kg · patients being treated for HIV infection
It is very uncertain whether PRO 140 changes antiviral response: 0.5 mg/kg compared with placebo (very low certainty).
1 finding from 1 review
Individual nadir changes in HIV‐1 RNA level ‐ 5mg/Kg · patients being treated for HIV infection
1 finding from 1 review
Individual nadir changes in HIV‐1 RNA level: 10 mg/kg · patients being treated for HIV infection
1 finding from 1 review
Individual nadir changes in HIV‐1 RNA level ‐ 162 mg weekly · patients being treated for HIV infection
1 finding from 1 review
Individual nadir changes in HIV‐1 RNA level ‐ 324 mg weekly · patients being treated for HIV infection
1 finding from 1 review
Individual nadir changes in HIV‐1 RNA level ‐ 324 mg biweekly · patients being treated for HIV infection
1 finding from 1 review
Antiviral response ‐ 2mg/Kg · patients being treated for HIV infection
It is very uncertain whether PRO 140 changes antiviral response: 2 mg/kg compared with placebo (very low certainty).
1 finding from 1 review
Antiviral response ‐ 5mg/Kg · patients being treated for HIV infection
It is very uncertain whether PRO 140 changes antiviral response: 5 mg/kg compared with placebo (very low certainty).
1 finding from 1 review
Antiviral response: 10 mg/kg · patients being treated for HIV infection
It is very uncertain whether PRO 140 changes antiviral response: 10 mg/kg compared with placebo (very low certainty).
1 finding from 1 review
Antiviral response ‐ 162 mg weekly · patients being treated for HIV infection
It is very uncertain whether PRO 140 changes antiviral response: 162 mg weekly compared with placebo (very low certainty).
1 finding from 1 review
Antiviral response ‐ 324 mg weekly · patients being treated for HIV infection
It is very uncertain whether PRO 140 changes antiviral response: 324 mg weekly compared with placebo (very low certainty).
1 finding from 1 review
Antiviral response ‐ 324 mg biweekly · patients being treated for HIV infection
It is very uncertain whether PRO 140 changes antiviral response: 324 mg biweekly compared with placebo (very low certainty).
1 finding from 1 review